Sanofi (SNY) Current Leases (2019 - 2026)
Sanofi (SNY) posted Current Leases of $263.9 million for Q2 2026, down 16.66% sequentially from $316.6 million in Q4 2025, and down 7.5% YoY from $285.3 million in Q2 2025.
Sanofi (SNY) Current Leases (2019 - 2026) Analysis & Trends
Sanofi has reported Current Leases for 8 years, with the latest figure at $263.9 million in Q2 2026.
- Quarterly Current Leases fell 7.5% year-over-year to $263.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $263.9 million (down 7.5% YoY) and the FY2025 annual result came in at $316.6 million, up 13.52% from the prior year.
- Current Leases declined to $263.9 million in Q2 2026 per SNY's latest filing, from $316.6 million in the prior quarter.
- Over five years, Current Leases peaked at $316.6 million in Q4 2025 and troughed at $246.5 million in Q2 2022.
- A 5-year average of $282.8 million and a median of $282.6 million in 2022 frame the typical range for Current Leases.
- The sharpest annual moves came in 2022 and 2025: Current Leases dropped 17.13% in 2022, then increased 13.52% in 2025.
- Over 5 years, Current Leases stood at $282.6 million in 2022, then grew by 4.7% to $295.9 million in 2023, then slipped by 5.74% to $278.9 million in 2024, then increased by 13.52% to $316.6 million in 2025, then fell by 16.66% to $263.9 million in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $263.9 million, $316.6 million, and $285.3 million for Q2 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 263.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 263.86 Mn |
| Dec 31, 2025 | 316.62 Mn |
| Jun 30, 2025 | 285.25 Mn |
| Dec 31, 2024 | 278.90 Mn |
| Jun 30, 2024 | 300.45 Mn |
| Dec 31, 2023 | 295.88 Mn |
| Jun 30, 2023 | 275.50 Mn |
| Dec 31, 2022 | 282.61 Mn |
| Jun 30, 2022 | 246.49 Mn |
| Dec 31, 2021 | 307.73 Mn |
| Jun 30, 2021 | 297.46 Mn |
| Dec 31, 2020 | 276.61 Mn |
| Jun 30, 2020 | 273.16 Mn |
| Dec 31, 2019 | 2.44 Mn |
| Jun 30, 2019 | 269.67 Mn |